ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) Files An 8-K Other EventsItem 8.01
On January 24, 2017, Zosano Pharma Corporation received a letter from the Director of NASDAQ Listing Qualifications notifying the Company that it has regained compliance with the requirement of the NASDAQ Stock Market to maintain a minimum bid price of $1.00 per share.
The letter noted that as of the close of trading on January 20, 2017, the Company evidenced a closing bid price of its common stock that was greater than or equal to the $1.00 minimum requirement for at least ten consecutive trading days. Accordingly, the Company has regained compliance with NASDAQ Listing Rule 5550(a)(2) and NASDAQ considers the matter closed.
2
About ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN)
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company’s short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon. ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) Recent Trading Information
ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) closed its last trading session up +0.04 at 1.17 with 72,876 shares trading hands.